Literature DB >> 26310626

A novel mouse model for ataxia-telangiectasia with a N-terminal mutation displays a behavioral defect and a low incidence of lymphoma but no increased oxidative burden.

Andrew Campbell1, Brittany Krupp2, Jared Bushman3, Mark Noble2, Christoph Pröschel2, Margot Mayer-Pröschel4.   

Abstract

Ataxia-telangiectasia (A-T) is a rare multi-system disorder caused by mutations in the ATM gene. Significant heterogeneity exists in the underlying genetic mutations and clinical phenotypes. A number of mouse models have been generated that harbor mutations in the distal region of the gene, and a recent study suggests the presence of residual ATM protein in the brain of one such model. These mice recapitulate many of the characteristics of A-T seen in humans, with the notable exception of neurodegeneration. In order to study how an N-terminal mutation affects the disease phenotype, we generated an inducible Atm mutant mouse model (Atm(tm1Mmpl/tm1Mmpl), referred to as A-T [M]) predicted to express only the first 62 amino acids of Atm. Cells derived from A-T [M] mutant mice exhibited reduced cellular proliferation and an altered DNA damage response, but surprisingly, showed no evidence of an oxidative imbalance. Examination of the A-T [M] animals revealed an altered immunophenotype consistent with A-T. In contrast to mice harboring C-terminal Atm mutations that disproportionately develop thymic lymphomas, A-T [M] mice developed lymphoma at a similar rate as human A-T patients. Morphological analyses of A-T [M] cerebella revealed no substantial cellular defects, similar to other models of A-T, although mice display behavioral defects consistent with cerebellar dysfunction. Overall, these results suggest that loss of Atm is not necessarily associated with an oxidized phenotype as has been previously proposed and that loss of ATM protein is not sufficient to induce cerebellar degeneration in mice.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26310626      PMCID: PMC5007607          DOI: 10.1093/hmg/ddv342

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  108 in total

1.  IMMUNOLOGIC DEFICIENCY IN ATAXIA TELANGIECTASIA.

Authors:  A H EISEN; G KARPATI; T LASZLO; F ANDERMANN; J P ROBB; H L BACAL
Journal:  N Engl J Med       Date:  1965-01-07       Impact factor: 91.245

2.  Genotype-phenotype relationships in ataxia-telangiectasia and variants.

Authors:  S Gilad; L Chessa; R Khosravi; P Russell; Y Galanty; M Piane; R A Gatti; T J Jorgensen; Y Shiloh; A Bar-Shira
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

3.  Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma.

Authors:  Tracy J Lightfoot; Christine F Skibola; Alex G Smith; Matthew S Forrest; Peter J Adamson; Gareth J Morgan; Paige M Bracci; Eve Roman; Martyn T Smith; Elizabeth A Holly
Journal:  Haematologica       Date:  2006-09       Impact factor: 9.941

Review 4.  Cancer in ataxia-telangiectasia patients.

Authors:  F Hecht; B K Hecht
Journal:  Cancer Genet Cytogenet       Date:  1990-05

5.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Authors:  Y Xu; T Ashley; E E Brainerd; R T Bronson; M S Meyn; D Baltimore
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

Review 6.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

Review 7.  X-linked disorders with cerebellar dysgenesis.

Authors:  Ginevra Zanni; Enrico S Bertini
Journal:  Orphanet J Rare Dis       Date:  2011-05-15       Impact factor: 4.123

8.  Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice.

Authors:  P R Borghesani; F W Alt; A Bottaro; L Davidson; S Aksoy; G A Rathbun; T M Roberts; W Swat; R A Segal; Y Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

9.  Predominance of null mutations in ataxia-telangiectasia.

Authors:  S Gilad; R Khosravi; D Shkedy; T Uziel; Y Ziv; K Savitsky; G Rotman; S Smith; L Chessa; T J Jorgensen; R Harnik; M Frydman; O Sanal; S Portnoi; Z Goldwicz; N G Jaspers; R A Gatti; G Lenoir; M F Lavin; K Tatsumi; R D Wegner; Y Shiloh; A Bar-Shira
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

10.  Functional and molecular defects of hiPSC-derived neurons from patients with ATM deficiency.

Authors:  L Carlessi; E Fusar Poli; G Bechi; M Mantegazza; B Pascucci; L Narciso; E Dogliotti; C Sala; C Verpelli; D Lecis; D Delia
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

View more
  8 in total

Review 1.  The recent advances in non-homologous end-joining through the lens of lymphocyte development.

Authors:  Xiaobin S Wang; Brian J Lee; Shan Zha
Journal:  DNA Repair (Amst)       Date:  2020-06-25

2.  Ataxia telangiectasia mutated is required for efficient proximal airway epithelial cell regeneration following influenza A virus infection.

Authors:  Rachel Warren; Andrew M Dylag; Molly Behan; William Domm; Min Yee; Margot Mayer-Pröschel; Luis Martinez-Sobrido; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-02-23       Impact factor: 6.011

3.  Ataxia-telangiectasia mutated is required for the development of protective immune memory after influenza A virus infection.

Authors:  Rachel Warren; William Domm; Min Yee; Andrew Campbell; Jane Malone; Terry Wright; Margot Mayer-Pröschel; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-11       Impact factor: 5.464

4.  A novel, ataxic mouse model of ataxia telangiectasia caused by a clinically relevant nonsense mutation.

Authors:  Harvey Perez; May F Abdallah; Jose I Chavira; Angelina S Norris; Martin T Egeland; Karen L Vo; Callan L Buechsenschuetz; Valentina Sanghez; Jeannie L Kim; Molly Pind; Kotoka Nakamura; Geoffrey G Hicks; Richard A Gatti; Joaquin Madrenas; Michelina Iacovino; Peter J McKinnon; Paul J Mathews
Journal:  Elife       Date:  2021-11-01       Impact factor: 8.713

Review 5.  ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition ≠ deletion.

Authors:  Demis Menolfi; Shan Zha
Journal:  Cell Biosci       Date:  2020-01-29       Impact factor: 7.133

6.  Hematopoietic Stem Cell Transplantation Restores Naïve T-Cell Populations in Atm-Deficient Mice and in Preemptively Treated Patients With Ataxia-Telangiectasia.

Authors:  Ruth Duecker; Patrick C Baer; Aileen Buecker; Sabine Huenecke; Lisa-Marie Pfeffermann; Ute Modlich; Shahrzad Bakhtiar; Peter Bader; Stefan Zielen; Ralf Schubert
Journal:  Front Immunol       Date:  2019-11-27       Impact factor: 7.561

7.  SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma.

Authors:  Kavita Bhalla; Sausan Jaber; Kayla Reagan; Arielle Hamburg; Karen F Underwood; Aditya Jhajharia; Maninder Singh; Binny Bhandary; Shambhu Bhat; Nahid M Nanaji; Ruching Hisa; Carrie McCracken; Heather Huot Creasy; Rena G Lapidus; Tami Kingsbury; Dirk Mayer; Brian Polster; Ronald B Gartenhaus
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

Review 8.  Inflammation, a significant player of Ataxia-Telangiectasia pathogenesis?

Authors:  Majid Zaki-Dizaji; Seyed Mohammad Akrami; Gholamreza Azizi; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Inflamm Res       Date:  2018-03-26       Impact factor: 4.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.